Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX–bevacizumab or FOLFIRI–bevacizumab: results …

…, AL Cohn, HI Hurwitz, M Kozloff, H Tezcan… - The …, 2012 - academic.oup.com
Background. The Avastin® Registry: Investigation of Effectiveness and Safety (ARIES) study
is a prospective, community-based observational cohort study that evaluated the …

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised …

…, V Holden, J Neidhart, M De Oliveira, H Tezcan… - The Lancet …, 2018 - thelancet.com
Background Initial results from the ongoing GALLIUM trial have shown that patients with
follicular lymphoma have a longer progression-free survival after first-line immunochemotherapy …

Early assessment of molecular progression and response by whole-genome circulating tumor DNA in advanced solid tumors

…, JC Close, A Tezcan, K Nesmith, H Tezcan… - Molecular cancer …, 2020 - AACR
Abstract Treatment response assessment for patients with advanced solid tumors is complex
and existing methods require greater precision. Current guidelines rely on imaging, which …

Validation of the 12-gene colon cancer recurrence score as a predictor of recurrence risk in stage II and III rectal cancer patients

…, M Lee, M Lopatin, H Tezcan… - Journal of the …, 2014 - academic.oup.com
Background The 12-gene Recurrence Score assay is a validated predictor of recurrence
risk in stage II and III colon cancer patients. We conducted a prospectively designed study to …

[HTML][HTML] Impact of the 12-gene colon cancer assay on clinical decision making for adjuvant therapy in stage II colon cancer patients

…, M Mishaeli, S Man, L Soussan-Gutman, H Tezcan… - Value in health, 2016 - Elsevier
Objectives To evaluate the impact of the 12-gene Colon Cancer Recurrence Score Assay—a
clinically validated prognosticator in stage II colon cancer after surgical resection—on …

Limited stage I and II follicular non-Hodgkin's lymphoma: the Nebraska Lymphoma Study Group experience

H Tezcan, JM Vose, M Bast, PJ Bierman… - Leukemia & …, 1999 - Taylor & Francis
The purpose of this study was to evaluate the outcome and prognostic factors of patients
with limited stage follicular non-Hodgkin's lymphoma treated prospectively by the Nebraska …

Early detection of molecular disease progression by whole-genome circulating tumor DNA in advanced solid tumors

…, H Wood, J Close, A Tezcan, K Nesmith, H Tezcan… - medrxiv, 2019 - medrxiv.org
Purpose Treatment response assessment for patients with advanced solid tumors is complex
and existing methods of assessment require greater precision for early disease assessment…

[PDF][PDF] İzmir Vizyonu ve Yönetişim

H Tezcan - içinde, 2007 - tepav.org.tr
Kentler yaşam alanlarının ötesinde bir anlama sahiptir. Artık ülkeler sahip olduğu kentsel
özellikleri ile kentlerin isimleri ile anılmaktadır. Tanınmanın ve kalıcı olmanın en etkin yolu da …

Prospective evaluation of a 12-gene assay on patient treatment decisions and physician confidence in mismatch repair-proficient (MMR-P) stage IIa colon cancer …

SR Alberts, LA Renfro, M Lopatin, H Tezcan, J Sloan… - 2014 - ascopubs.org
396 Background: The 12-gene Oncotype DXColon Cancer Assay is clinically validated as a
predictor of recurrence risk in stage II colon cancer patients following surgery. We previously …

Analysis of tumor DNA in urine as a highly sensitive liquid biopsy for patients with non-muscle invasive bladder cancer (NMIBC)

…, RD Abramson, M Crager, M Bonham, H Tezcan… - Clinical Cancer …, 2016 - AACR
Noninvasive detection of urine tumor DNA (utDNA) has the potential to augment the
diagnosis and management of bladder cancer. We sought to identify whether patient specific …